No abstract

BackgroundThis study aims to evaluate the safety, efficacy, and feasibility of a full randomized clinical trial of Ojeok-san in Korean female patients with cold hypersensitivity in the hands and feet.MethodsThis study is a multicenter, double-blinded, randomized, placebo-controlled, two-arm, parallel-group pilot clinical trial. A total of 60 participants will be enrolled and randomly assigned to the Ojeok-san treatment group or the placebo control group, in a 1:1 ratio using an Internet-based randomization system. Each group will be administered Ojeok-san or placebo three times per day for 8 weeks. The primary outcome will be the mean change in the Visual Analog Scale scores of cold hypersensitivity in the hands from baseline to week 8. Secondary outcomes will include the mean changes in the skin temperature of the extremities, recovery rate of the skin temperature of hands after cold stress test, and the score of Korean version of the WHO Quality of Life Scale abbreviated version.DiscussionThe findings of this study should provide meaningful information for a further large-scale, randomized controlled trial to confirm the safety and efficacy of Ojeok-san on cold hypersensitivity in the hands and feet in female patients.Trial registrationClinicalTrials.gov, ID: NCT03083522. Registered on 20 March 2017.Electronic supplementary materialThe online version of this article (10.1186/s13063-018-3013-9) contains supplementary material, which is available to authorized users.

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by complex symptoms. To treat AD without adverse effects, alternative therapeutic agents are required. The tubers of Helianthus tuberosus L. (Jerusalem artichoke) have been used in folk remedies for diabetes and rheumatism. However, its effect on AD development remains unknown. Therefore, this study examined the inhibitory effect of H. tuberosus (HT) on AD skin symptoms using an NC/Nga mouse model and HaCaT keratinocytes. The effect of HT and associated molecular mechanisms were evaluated in Dermatophagoides farina body (Dfb)-induced AD mice and tumor necrosis factor (TNF)-α/interferon (IFN)-γ-stimulated HaCaT keratinocytes by ELISA, western blot, and histological analysis. Topical HT administration attenuated AD skin symptoms in Dfb-induced AD mice, with a significant reduction in the dermatitis score and production of inflammatory mediators. HT also decreased epidermal thickness and mast cell infiltration. Moreover, HT restored filaggrin expression and inhibited adhesion molecules in the mice. These effects were confirmed in vitro. Furthermore, HT suppressed the activation of NF-κB, Akt, and mitogen-activated protein kinase (MAPK) signaling pathways induced by TNF-α/IFN-γ. These results suggest that HT is a potential therapeutic agent or supplement for skin allergic inflammatory diseases such as AD.

Background Cold hypersensitivity in the hands and feet (CHHF) is frequent in Asian countries including Korea. The quality of life can be degraded by the symptoms of CHHF. In particular, gynecological disorders such as menstrual pain, infertility, leucorrhea, and irregular bleeding may be related to CHHF. Sipjeondaebo-tang (SDT) is widely used in the treatment of various diseases including CHHF by balancing Yin and Yang, restoring the deterioration of physiological function, and improving immunity. However, the efficacy of SDT in the treatment of CHHF has not been assessed in clinical trials. Therefore, we aimed to investigate the feasibility of a full randomized clinical trial of SDT for the treatment of CHHF in Korean women through this trial. Methods This study will be a pilot, randomized, double-blind, two-arm, placebo-controlled, parallel-group, multicenter clinical trial. Women aged 19–59 years who present with CHHF will be recruited from five university hospitals. A total of 60 subjects will be randomly assigned to a treatment group (SDT) or a placebo group at a 1:1 ratio. The subjects will receive 3 g of either SDT or placebo three times daily for 8 weeks. The primary outcome measures will be the Visual Analogue Scale scores of CHHF. The secondary outcome measures will be changes in body temperature in both the hands and the feet as measured using a thermometer and the Korean version of the World Health Organization Quality of Life Scale Abbreviated Version. Discussion This will be the first trial to investigate the efficacy and safety of SDT in the treatment of CHHF. This study will provide basic clinical information regarding Korean herbal medicine treatment of CHHF and a clinical basis for designing a full randomized clinical trial. Trial registration ClinicalTrials.gov, NCT03374345 . Registered on 15 February 2018. Electronic supplementary material The online version of this article (10.1186/s13063-019-3286-7) contains supplementary material, which is available to authorized users.

Yin-tonic herbal medicines have been shown to possess properties that make skin healthy by nourishing within various organs of the body. However, the antiphotoaging effect of these medicines on the skin has not been fully studied. Photoaging occurs with prolonged sun exposure and causes skin damage and aging, with depletion of the dermal extracellular matrix and chronic alterations in skin structure, such as wrinkles. In this study, we assessed the antiphotoaging effects of eight yin-tonic herbal medicines on human skin cells and skin equivalents. The levels of type I procollagen and matrix metalloproteinase-1 (MMP-1) in ultraviolet B- (UVB-) irradiated CCD-986sk fibroblasts were measured, and then three medicines were chosen based on screening results. Using UVB-irradiated human skin equivalents, we evaluated the effect of three yin-tonic herbal medicines on histological changes of skin, epidermal and dermal thickness, and MMP-1 production. Furthermore, we observed collagen fiber content and protein expression of filaggrin in UVB-irradiated human skin equivalents. Yin-tonic herbal medicines increased type I procollagen levels and decreased the production of MMP-1 in UVB-irradiated CCD-986sk fibroblasts. The three selected yin-tonic herbal medicines recovered the collagen content and filaggrin expression via MMP-1 downregulation in UVB-irradiated human skin equivalents. Our results show that yin-tonic herbal medicines can prevent skin photoaging by reduction of MMP-1 levels and increasing the expression of moisturizing factors. Based on these results, we suggest that yin-tonic herbal medicines have the potential to be used as helpful agent for skin photoaging.